Abstract
Background: Recent reports of the remarkable therapeutic efficacy of 225Ac-labeled PSMA- 617 for therapy of metastatic castration-resistant prostate cancer have underlined the clinical potential of targeted alpha therapy.
Objective and Conclusion: This review describes methods for the production of 225Ac and its daughter nuclide 213Bi and summarizes the current clinical experience with both alpha emitters with particular focus on recent studies of targeted alpha therapy of bladder cancer, brain tumors, neuroendocrine tumors and prostate cancer.
Keywords: Targeted alpha therapy, alpha emitter, actinium-225, bismuth-213, nuclide production, clinical application.
Current Radiopharmaceuticals
Title:An Overview of Targeted Alpha Therapy with 225Actinium and 213Bismuth
Volume: 11 Issue: 3
Author(s): Alfred Morgenstern*, Christos Apostolidis, Clemens Kratochwil, Mike Sathekge, Leszek Krolicki and Frank Bruchertseifer
Affiliation:
- European Commission, Joint Research Centre, Directorate for Nuclear Safety and Security, Karlsruhe,Germany
Keywords: Targeted alpha therapy, alpha emitter, actinium-225, bismuth-213, nuclide production, clinical application.
Abstract: Background: Recent reports of the remarkable therapeutic efficacy of 225Ac-labeled PSMA- 617 for therapy of metastatic castration-resistant prostate cancer have underlined the clinical potential of targeted alpha therapy.
Objective and Conclusion: This review describes methods for the production of 225Ac and its daughter nuclide 213Bi and summarizes the current clinical experience with both alpha emitters with particular focus on recent studies of targeted alpha therapy of bladder cancer, brain tumors, neuroendocrine tumors and prostate cancer.
Export Options
About this article
Cite this article as:
Morgenstern Alfred*, Apostolidis Christos, Kratochwil Clemens, Sathekge Mike, Krolicki Leszek and Bruchertseifer Frank, An Overview of Targeted Alpha Therapy with 225Actinium and 213Bismuth, Current Radiopharmaceuticals 2018; 11 (3) . https://dx.doi.org/10.2174/1874471011666180502104524
DOI https://dx.doi.org/10.2174/1874471011666180502104524 |
Print ISSN 1874-4710 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4729 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cancer Nanotechnology: Emerging Role of Gold Nanoconjugates
Anti-Cancer Agents in Medicinal Chemistry Addressing the Challenge: Current and Future Directions in Ovarian Cancer Therapy
Current Gene Therapy Cytosine Methyltransferases as Tumor Markers
Current Genomics Pathogenesis, Experimental Models and Contemporary Pharmacotherapy of Irritable Bowel Syndrome: Story About the Brain-Gut Axis
Current Neuropharmacology Identification of Critical MicroRNA Gene Targets in Cervical Cancer Using Network Properties
MicroRNA A Prospective Study of the Clinical and Demographic Profile of Type 2 Diabetes Mellitus Patients Receiving Antidiabetic Drug Combinations
Current Diabetes Reviews Blockers of Voltage-Gated Sodium Channels for the Treatment of Central Nervous System Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Targeted Liposomal Drug Delivery in Cancer
Current Pharmaceutical Design Targets for Anti-metastatic Drug Development
Current Pharmaceutical Design Clinical Trials Targeting Advanced Cancers by Active Immunization of T-cell Defined Tumor Antigens
Current Pharmaceutical Design c-Myc: Linking Transformation and Genomic Instability
Current Molecular Medicine Anticancer and Cytotoxic Activities of [Cu(C6H16N2O2)2][Ni(CN)4] and [Cu(C6H16N2O2)Pd(CN)4] Cyanidometallate Compounds on HT29, HeLa, C6 and Vero Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Anti-Tumor Efficacy of Pyrvinium Pamoate Nanoliposomes in an Experimental Model of Melanoma
Anti-Cancer Agents in Medicinal Chemistry Multifunctional Anti-Cancer Nano-Platforms are Moving to Clinical Trials
Current Drug Metabolism Hepatic Effects of Duloxetine-I: Non-Clinical and Clinical Trial Data
Current Drug Safety Point of NO Return for Nitrergic Nerves in Diabetes: A New Insight into Diabetic Complications
Current Pharmaceutical Design Heat Shock Proteins as Prognostic Markers of Cancer
Current Cancer Drug Targets Targeted Alpha Therapy with 227Th-trastuzumab of Intraperitoneal Ovarian Cancer in Nude Mice
Current Radiopharmaceuticals The Functional Role of Long Non-coding RNA UCA1 in Human Multiple Cancers: a Review Study
Current Molecular Medicine Influence of Pulsing Electromagnetic Field Therapy on Gene Expression in Muscle Cells, Peripheral Circulation, and Metabolic Factors in Aging Adults
Current Chemical Biology